Akari Therapeutics Announces Appointment of David Horn Solomon as CEO
August 21, 2017 07:05 ET
|
Akari Therapeutics, Plc
NEW YORK and LONDON, Aug. 21, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX) is pleased to announce that Dr David Horn Solomon will be appointed as the company’s new chief executive...
Akari Therapeutics to Present at the 37th Annual Canaccord Genuity Growth Conference
August 10, 2017 07:00 ET
|
Akari Therapeutics, Plc
NEW YORK and LONDON, Aug. 10, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that Clive Richardson, Chief...
Akari Therapeutics to Present Data from Phase 2 PNH Trial of Coversin at the 22nd Congress of the European Hematology Association
June 23, 2017 07:00 ET
|
Akari Therapeutics, Plc
NEW YORK and LONDON, June 23, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), a clinical-stage biopharmaceutical company, is presenting a poster today at the 22nd Congress of the European...
Akari Therapeutics Announces Edison’s Withdrawal of Edison Report titled “Akari’s Coversin matches Soliris in Phase II”
April 27, 2017 06:46 ET
|
Akari Therapeutics, Plc
NEW YORK and LONDON, April 27, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, released today a statement that Edison...
Akari Therapeutics Demonstrates Positive Response with Coversin in Ongoing Phase 2 PNH Trial and in Additional Clinical Targets
April 24, 2017 07:15 ET
|
Akari Therapeutics, Plc
-Interim Phase 2 PNH data demonstrate positive response with Coversin™-Phase 3 PNH program expected to commence in 4Q2017-Data from preclinical aHUS model demonstrates positive results-New preclinical...
Akari Therapeutics to Present at the Jefferies Complement Symposium
April 03, 2017 07:00 ET
|
Akari Therapeutics, Plc
NEW YORK and LONDON, April 03, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that Dr. Gur Roshwalb, Chief...
Akari Therapeutics Announces FDA Fast Track Designation For Coversin
March 30, 2017 16:02 ET
|
Akari Therapeutics, Plc
NEW YORK and LONDON, March 30, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that the US Food and Drug...
Akari Therapeutics Announces R&D Day on April 24, 2017
March 17, 2017 07:00 ET
|
Akari Therapeutics, Plc
NEW YORK and LONDON, March 17, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that it will hold a Research...
Akari Therapeutics to Present at the 29th Annual ROTH Conference
March 07, 2017 07:00 ET
|
Akari Therapeutics, Plc
NEW YORK and LONDON, March 07, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that Dr. Gur Roshwalb, Chief...
Akari Therapeutics to Attend Upcoming Investor Conferences in February
January 31, 2017 07:00 ET
|
Akari Therapeutics, Plc
NEW YORK and LONDON, Jan. 31, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that senior management will...